Drugs.com - Clinical Trials

Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-Positive NSCLC

CAMBRIDGE, Mass., June 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced positive...

Jun 26, 2025 - 03:05
 0
Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-Positive NSCLC
CAMBRIDGE, Mass., June 24, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced positive...
Read More

Tags:

Previous Article

Global eNewsletter of June 26, 2025

Next Article

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation fo...

Related Posts

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

BeiGene Provides Update on the Ociperlimab (BGB-A1217) ...

May 12, 2025  0

Boehringer’s New Zongertinib Data Demonstrates Durable and Clinically Meaningful Results in Patients with HER2 (ERBB2)-Mutant Advanced NSCLC

Boehringer’s New Zongertinib Data Demonstrates Durable ...

May 12, 2025  0

Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease

Rocket Pharmaceuticals Provides Update on Phase 2 Clini...

May 30, 2025  0